A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
708actual
Sites
160
Countries
Argentina, Australia, Belgium +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-04-30 | actual | When the study began enrolling |
| Primary completion | 2025-03-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-24 | actual | The whole study's end, after follow-up |
| First posted | 2021-04-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Axial Spondylarthritis (axSpA)
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants with a Total Spinal Pain Score < 4 and >= 2 Unit (0 - 10) Improvement
measured Baseline (Week 0) to Week 12
Percentage of Participants Maintaining Total Spinal Pain < 4 Among Participants Who Achieved Total Spinal Pain < 4 and >= 2 unit (0 - 10) Improvement from Baseline at Week 12
measured Week 52
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed